To include your compound in the COVID-19 Resource Center, submit it here.

Ilaris canakinumab: Phase III data

The 12-week, double-blind, double-dummy Phase III B-RELIEVED II trial in about 226 patients with acute gout showed that a single subcutaneous injection of 150 mg Ilaris met the co-primary

Read the full 297 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE